

Africure Pharmaceuticals Ltd

(Incorporated in the Republic of Mauritius)

(Registration number: C145852 C1/GBL)

Having its registered address at

6th Floor, Tower A, 1 Cybercity, Ebene, Republic of Mauritius

(**"Africure"** or **"the Company"**)



[Africure and its subsidiaries are collectively referred to as the **"Group"**]

FURTHER EXTENSION OF DEADLINE TO RELEASE UNAUDITED FINANCIAL RESULTS

Shareholders of Africure and interested parties are referred to the communique released by the Company on 7th August 2026 wherein the Board of directors of Africure (the **"Board"**) had announced that the Stock Exchange of Mauritius (**"SEM"**) approved the extension of the deadline for publishing the Company's abridged unaudited financial statements for the quarter ended 30 June 2026 until 31st August 2026.

Due to the unavailability of directors, the Board is unable to hold its board meeting within the extended deadline of 31st August 2026, at which the abridged unaudited financial statements for the quarter ended 30th June 2026 would have been considered and approved for release.

Consequently, and following an application made to the SEM, the Company has obtained formal approval of the SEM to further extend the deadline for publishing its abridged unaudited financial statements for the quarter ended 30 June 2026, until 30th September 2026.

By order of the Board

27th August 2026

For further information please contact:

SEM Authorised Representative & Sponsor



+230 402 0890

Company Secretary



+230 403 6000

This notice is issued pursuant to SEM Listing Rule 11.3. The Board of Africure accepts full responsibility for the accuracy of the information contained in this announcement.